Table 1.
Immunization Treatment Allocation and Highly Active Antiretroviral Therapy Regimen
| Subject | Immunization treatment allocation | HAART regimen |
|---|---|---|
| 1 | Placebo | Lopinavir/r, 3TC, ABC |
| 2 | Remune + ALVAC | Lopinavir/r, 3TC, ABC |
| 3 | Placebo | Lopinavir/r, 3TC, d4T |
| 4 | Remune + ALVAC | Lopinavir/r, 3TC, AZT |
| 5 | Remune + ALVAC | Lopinavir/r, 3TC, ABC |
| 6 | ALVAC | Lopinavir/r, 3TC, AZT |
| 7 | Remune + ALVAC | Saquinavir/r, 3TC, AZT |
| 8 | Placebo | Lopinavir/r, 3TC, ABC |
| 9 | Remune + ALVAC | Nelfinavir, 3TC, AZT, ABC |
| 10 | Placebo | Lopinavir/r, 3TC, TDF |
| 11 | Remune + ALVAC | Lopinavir/r, TDF, FTC |
| 12 | ALVAC | Lopinavir/r, 3TC, d4T |
| 13 | Placebo | Lopinavir/r, 3TC, d4T |
| 14 | Remune + ALVAC | Indinavir, AZT, 3TC |
HAART, highly active antiretroviral therapy; r, ritonavir boosting dose; 3TC, lamivudine; ABC, abacavir; d4T, stavudine; AZT, zidovudine; TDF, tenofovir; FTC, emtricitabine.